SLQT September 15 judicial ruling expected move?

For "SLQT September 15 judicial ruling historical move size": across 5 resolved past events on file, SLQT saw a median absolute move of ~39.6% to the outcome date, with price often settling inside the prior scenario band (backward-looking only). See the historical catalyst schedule on Scouter for SLQT (past outcomes only; forward bull/bear targets unlock with a Starter or Premium free trial).

SLQT judicial ruling expected move?

For "SLQT judicial ruling historical move size": across 5 resolved past events on file, SLQT saw a median absolute move of ~39.6% to the outcome date, with price often settling inside the prior scenario band (backward-looking only). See the historical catalyst schedule on Scouter for SLQT (past outcomes only; forward bull/bear targets unlock with a Starter or Premium free trial).

SLQT average generic catalyst stock move?

For "SLQT average generic catalyst stock move": across 5 resolved past events on file, SLQT saw a median absolute move of ~39.6% to the outcome date, with price often settling inside the prior scenario band (backward-looking only). See the historical catalyst schedule on Scouter for SLQT (past outcomes only; forward bull/bear targets unlock with a Starter or Premium free trial).

SLQT (SelectQuote, Inc.) — Stock Analysis, Catalysts & AI Research

SLQTSelectQuote, Inc.

FinancialsInsurance Brokers

The Read

2% on Q2 2026 earnings due to weak Peak AEP results and poor guidance, then dropped 28%.

Dec 15, 2026 — Potential Equity Raise or Strategic Alternatives Announcement

Chart by TradingView

The schedule

Tue15Dec
A crucial window for addressing the $403 million debt pile before year-end, potentially through dilution or a strategic sale.
Sun14Feb
Full-year results and initial FY 2027 guidance following the conclusion of the critical AEP selling season.
Thu20May
Q1 2027 earnings focused entirely on liquidity runway, cost containment, and early off-AEP efficiency.

Past

Thu1Oct
President Trump is expected to outline his administration's forward-looking Medicare Advantage regulatory framework.
Tue15Sep
Expected judicial ruling on the Motion to Dismiss (MTD) regarding the pending federal securities lawsuit.
Mon1Jun
Actual outcome: Bear · $0.92 at outcome
The stock fell 12.6% through the outcome date as the company failed to announce a positive resolution to its near-term liquidity hurdles. Instead, sentiment was dragged down by news of a federal securities lawsuit investigating whether SelectQuote insiders breached their fiduciary duties and misrepresented information to shareholders. The combination of unresolved debt concerns and emerging legal risks drove the stock's continued decline toward the bear floor.
Resolution of near-term liquidity hurdles, with potential for dilutive financing or high-interest term loans.
Mon11May
Actual outcome: Bull · $1.19 at outcome
SelectQuote delivered a strong Q3 earnings beat, reporting EPS of $0.15 against estimates of a $0.02 loss, and grew consolidated revenue year-over-year to $430.9 million. These robust fundamental results and a subsequent upgrade to a Zacks Strong Buy initially drove the stock up 14.4%, although shares later retraced to $1.00 by late May.
Q3 results will reveal off-AEP marketing efficiency and policy persistency ahead of structural 2027 changes.
Mon6Apr
Actual outcome: Bull · $0.65 at outcome
SelectQuote shares rose 7.5% following the CMS 2027 Medicare Advantage Final Rate Announcement, indicating that the finalized rates were viewed favorably or were better than feared for the company's Medicare distribution business. The bullish momentum continued in the following weeks with the stock reaching $1.00 by late May, easily shrugging off boilerplate shareholder litigation investigations announced shortly after the event.
The final decision by CMS on reimbursement rates for 2027. Following the preliminary 0.09% rate shock in February, any upward revision is a critical lifeline.
Sun1Mar
Actual outcome: Bear · $0.61 at outcome
SelectQuote shares fell 28.9%, dropping well below the $1.08 bear floor. The decline was driven by negative sentiment surrounding a federal securities lawsuit investigating whether company insiders breached their fiduciary duties by misrepresenting information to shareholders, which weighed heavily on the stock.
Release of the highly anticipated CMS Final Rule. This is the single largest asymmetric risk event, clarifying allowable broker compensation, policy eligibility, and marketing practices for Medicare Advantage. A benign/clarifying rule is a massive de-risking event; a harsh rule risks the business model.
Thu5Feb
Actual outcome: Bear · $0.84 at outcome
SelectQuote reported Q2 2026 EPS of $0.27, exactly matching consensus estimates. Despite meeting bottom-line expectations, the stock dropped 18.2% and breached the bear floor, driven by underlying weakness in Peak AEP results and disappointing forward guidance. The lack of an earnings beat coupled with concerns over future enrollment volumes and profitability prompted a sharp sell-off.
Release of earnings for the quarter ending 2025-12-31, which covers the critical Annual Enrollment Period (AEP). Focus will be on policy Lifetime Value (LTV) and Customer Acquisition Cost (CAC) improvements to validate the turnaround strategy.